Leendert van den Bos
CEO
Dr. Leendert van den Bos obtained his MSc- and PhD-degree in bio-organic chemistry from Leiden University. He joined Organon BioSciences as a Scientist in 2007 and worked subsequently for Schering-Plough, Merck Sharp & Dohme and Aspen Pharmacare mostly in the field of Process Research & Development. Leendert holds an Executive MBA from Nyenrode University.
Rodney Lax
Business Development Consultant
Dr. Rodney Lax was trained as a biochemist in the UK and worked many years in academia amongst others as Associate Professor of Physiological Chemistry at the University of Essen in 1985. From 1986 onwards, he focused his attention on peptide therapeutics, working at a number of small biotech and manufacturing organizations including PolyPeptide Group and EnzyPep. Dr. Lax has been Director on the Board of the Peptide Therapeutics Foundation and is a member of Boulder Peptide Society Scientific Advisory Board.
Robert Naasz
Business Development Consultant
Dr. Robert Naasz obtained his PhD in Organic Chemistry at the University of Groningen with Nobel prize winner Prof. B.L. Feringa. He joined Diosynth (Oss, The Netherlands) as a Scientist in 2002 and worked subsequently for Organon Biosciences, Schering-Plough, Merck Sharp & Dohme mostly in the field of Process Research & Development. From 2010 onwards Robert was responsible for strategic sourcing and purchasing for the Aspen Pharmacare API production site in Oss, running various high impact sourcing projects with companies in Asia. In 2019 he joined EnzyTag as Business Development Manager responsible for the Asia region.
Roger McDonald
Business Development Consultant
Roger McDonald graduated in Chemistry from the University of Birmingham in the UK in 1987. He spent 20 years with Ubichem, a privately owned UK-based fine chemical company, becoming a board member at the age of 29. He played a key role in the foundation and development of a development and manufacturing site in Budapest. In 2007 he joined Cambridge Major Laboratories in the Netherlands with responsibility for all European business development activities. Spent ten years as a member of the site management. From 2015 – 2018 he served as BD consultant for EnzyTag’s predecessor EnzyPep. Roger joined EnzyTag in the beginning of 2019.